Vaxchora
Total Payments
$1.0M
Transactions
376
Doctors
41
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $406.05 | 8 | 8 |
| 2023 | $87,850 | 25 | 1 |
| 2022 | $138,863 | 53 | 1 |
| 2021 | $183,750 | 62 | 1 |
| 2020 | $443,699 | 80 | 2 |
| 2019 | $185,824 | 148 | 32 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $547,630 | 159 | 52.6% |
| Unspecified | $314,882 | 62 | 30.3% |
| Royalty or License | $89,718 | 3 | 8.6% |
| Honoraria | $67,309 | 26 | 6.5% |
| Travel and Lodging | $12,239 | 53 | 1.2% |
| Food and Beverage | $8,613 | 73 | 0.8% |
Payments by Type
General
$725,510
314 transactions
Research
$314,882
62 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (CholeraVaccine, Live, Oral) in Children 2 to <18 Years of Age | Emergent BioSolutions Inc. | $228,832 | 0 |
| Phase 4 Placebo Controlled Study to Assess the Safety and Immunogenicity of Vaxchora (Cholera Vaccine, Live, Oral) in Infants 6 to <24 | Emergent BioSolutions Inc. | $41,900 | 1 |
| VAXCHORA Pediatric Study to Assess Safety and Immunogenicity | Emergent BioSolutions Inc. | $14,900 | 1 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | Emergent BioSolutions Inc. | $10,413 | 1 |
| General Vachora product program consulting | Emergent BioSolutions Inc. | $9,100 | 1 |
| Australia Regulatory Work | Emergent BioSolutions Inc. | $5,038 | 1 |
| Vachora post marketing publication consulting | Emergent BioSolutions Inc. | $3,200 | 1 |
| Australia regulatory work | Emergent BioSolutions Inc. | $1,500 | 1 |
Top Doctors Receiving Payments for Vaxchora
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pediatrics | Madera, CA | $627,680 | 197 |
| Unknown | — | Baltimore, MD | $318,550 | 24 |
| , MD | Pediatric Infectious Diseases | Carmel, IN | $57,854 | 83 |
| , M.D | Infectious Disease | Burlingame, CA | $17,730 | 23 |
| , MD | Family Medicine | Vancouver, WA | $6,944 | 6 |
| , MD PHD | Research | Charlottesville, VA | $6,000 | 3 |
| , MD | Pediatrics | Bethesda, MD | $389.39 | 1 |
| , MD | Internal Medicine | Chevy Chase, MD | $344.48 | 1 |
| , M.D | Pediatric Endocrinology | Baltimore, MD | $339.78 | 1 |
| , M.D | Pediatrics | New York, NY | $339.78 | 1 |
| , M.D | Diagnostic Radiology | New York, NY | $339.78 | 1 |
| , M.D | Pediatrics | New York, NY | $339.78 | 1 |
| , M.D., M.S | Pediatrics | New York, NY | $339.78 | 1 |
| , M.D | Infectious Disease | Oakland, CA | $321.61 | 3 |
| , MD | Internal Medicine | Washington, DC | $277.39 | 1 |
| , MD | Ophthalmology | Elmwood Park, NJ | $212.02 | 2 |
| , M.D | Internal Medicine | New York, NY | $212.02 | 2 |
| , FNP | Family | Farmington, NM | $161.78 | 1 |
| , MD | Infectious Disease | Boston, MA | $124.45 | 1 |
| , M.D | Internal Medicine | New York, NY | $115.68 | 1 |
| , MD | Public Health & General Preventive Medicine | Decatur, GA | $113.14 | 1 |
| , MD | Emergency Medicine | Memphis, TN | $110.06 | 1 |
| , M.D | Family Medicine | Indianapolis, IN | $106.60 | 1 |
| , MD | Family Medicine | Poughkeepsie, NY | $106.01 | 1 |
| , MD | Allergy & Immunology | New York, NY | $106.01 | 1 |
Ad
Manufacturing Companies
- Emergent BioSolutions Inc. $1.0M
- Bavarian Nordic A/S $406.05
Product Information
- Type Drug
- Total Payments $1.0M
- Total Doctors 41
- Transactions 376
About Vaxchora
Vaxchora is a drug associated with $1.0M in payments to 41 healthcare providers, recorded across 376 transactions in the CMS Open Payments database. The primary manufacturer is Emergent BioSolutions Inc..
Payment data is available from 2019 to 2024. In 2024, $406.05 was paid across 8 transactions to 8 doctors.
The most common payment nature for Vaxchora is "Consulting Fee" ($547,630, 52.6% of total).
Vaxchora is associated with 8 research studies, including "Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (CholeraVaccine, Live, Oral) in Children 2 to <18 Years of Age" ($228,832).